Published in Gene Therapy Weekly, September 16th, 2004
"This is an important achievement in the development of an IL-9 neutralizing antibody product based on the identification of IL-9 as a genetic root-cause of asthma. An IL-9 neutralizing antibody is the culmination of many years of intensive genetic, immunologic, and developmental research at Genaera, the Ludwig Institute of Cancer Research, and a number of other premier academic institutions," said Roy C. Levitt, MD, president and CEO. "We believe that if this product is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.